Feline Hyperthyroidism: Virbac acquires Felanorm

Acquisition provides Virbac with a globally leading specialty product to improve the quality of life for senior cats.

CARROS, France, Dec. 17, 2025 /PRNewswire/ -- We are delighted to announce the acquisition of a globally leading drug for the treatment of feline hyperthyroidism from Norbrook. Virbac will immediately begin selling the Felanorm® (methimazole) Oral Solution in the U.S. and under the Thyronorm brand in the United Kingdom, Australia, and New Zealand. In Europe, distribution will continue to be managed by Boehringer Ingelheim and Elanco (in Germany) before being gradually taken over by Virbac. This solution is a strong fit to our existing portfolio and capabilities. The transaction, valued at around £100 million, is expected to be accretive to Virbac Group sales growth and EBITDA margin from year 1.